Millennium Management LLC Invests $962,000 in Cellectis S.A. (NASDAQ:CLLS)

Millennium Management LLC acquired a new position in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 534,551 shares of the biotechnology company's stock, valued at approximately $962,000. Millennium Management LLC owned approximately 0.96% of Cellectis at the end of the most recent reporting period.

Separately, B Group Inc. acquired a new stake in shares of Cellectis in the 4th quarter valued at about $5,547,000. Institutional investors and hedge funds own 63.90% of the company's stock.

Cellectis Stock Performance

CLLS stock traded down $0.03 during trading on Friday, hitting $1.41. 70,273 shares of the company's stock traded hands, compared to its average volume of 144,712. The stock has a market capitalization of $78.37 million, a price-to-earnings ratio of -1.08 and a beta of 2.92. Cellectis S.A. has a 52 week low of $1.10 and a 52 week high of $2.62. The stock has a fifty day moving average price of $1.44 and a two-hundred day moving average price of $1.54. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). The business had revenue of $12.03 million for the quarter, compared to the consensus estimate of $12.71 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. As a group, equities analysts anticipate that Cellectis S.A. will post -0.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wall Street Zen lowered Cellectis from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Barclays decreased their target price on Cellectis from $5.00 to $4.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.